Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Introduction to Treatment Guidelines

The American Urological Association recommends beginning with behavioral modifications and self-care practices for all patients, then escalating systematically through oral medications, intravesical therapies, and reserving advanced interventions only for refractory cases 1, 2, 3

Patients should start with conservative measures, including dietary management, before any pharmacologic intervention 1, 2, 3
Eliminate known bladder irritants, including coffee, citrus products, and spicy foods, to reduce symptoms 1, 2, 3
Implement an elimination diet to identify personal trigger foods 1, 2, 3
Alter urine concentration through strategic fluid management to dilute urinary irritants 1, 2, 3
Apply local heat or cold over the bladder or perineum for symptomatic pain relief 1, 2, 3
Practice stress management techniques, such as meditation and imagery, to reduce stress 1, 2, 3
Perform pelvic floor muscle relaxation exercises, but not strengthening exercises, to avoid worsening symptoms 1, 2, 3

The American College of Physicians recommends starting with amitriptyline, 10 mg daily, and titrating up to 100 mg per day as tolerated 1, 2, 3
Amitriptyline has Grade B evidence showing superiority to placebo for symptom improvement 1, 2
Common side effects of amitriptyline include sedation, drowsiness, and nausea 1
Pentosan polysulfate sodium is the only FDA-approved oral medication for IC/BPS, at 100 mg three times daily 1, 2, 3
Pentosan polysulfate sodium requires mandatory ophthalmologic monitoring due to risk of macular damage and ocular toxicity 1, 2, 3

Heparin repairs the damaged glycosaminoglycan (GAG) layer of the bladder and provides clinically significant symptom improvement 1, 2, 3
Lidocaine provides rapid onset temporary relief of bladder pain 1, 2, 3

Perform cystoscopy to determine anatomic bladder capacity and identify fibrosis-related capacity reduction 2, 3
Avoid high-pressure and long-duration hydrodistension to minimize risk of bladder rupture and sepsis 2, 3

Perform fulguration and/or injection of triamcinolone for significant symptom relief if Hunner lesions are identified on cystoscopy 1, 2, 3

Sacral neuromodulation has Grade C evidence with limited sample sizes and lack of durable follow-up 1, 2, 3
Cyclosporine A has Grade C evidence and is not FDA-approved for IC/BPS 1, 2, 3
Intradetrusor botulinum toxin A has Grade C evidence and is not FDA-approved for IC/BPS, and patients must be willing to accept the possibility of requiring intermittent self-catheterization post-treatment 1, 2

Initiate and maintain multimodal pain management approaches throughout treatment, with non-opioid alternatives preferred due to the chronic nature of the condition 1, 3
Pain management alone does not constitute sufficient treatment—underlying bladder symptoms must also be addressed 1, 3

Long-term oral antibiotics have no benefit over placebo and risk antibiotic resistance 2, 3
Intravesical BCG has no efficacy and potentially life-threatening adverse events 2, 3
Intravesical resiniferatoxin has no significant benefit and high adverse event rates 2, 3
High-pressure, long-duration hydrodistension increases risk of bladder rupture and sepsis 2, 3
Systemic long-term glucocorticoids have serious adverse events outweighing minimal benefits 2, 3

Never prescribe pelvic floor strengthening exercises—only relaxation techniques should be used 1, 2, 3
Document baseline symptoms using validated tools, such as the Genitourinary Pain Index (GUPI) or Interstitial Cystitis Symptom Index (ICSI) 1
Educate patients that IC/BPS is a chronic condition with periods of flares and remissions requiring long-term management 1, 3
Treatment efficacy for any individual is unpredictable—multiple therapeutic options may need to be tried before adequate symptom control is achieved 4, 1, 3
Ensure regular ophthalmologic examinations for patients using pentosan polysulfate 1, 2, 3

IC/BPS should be strongly considered in men whose pain is perceived to be related to the bladder 4
Certain men have symptoms meeting criteria for both IC/BPS and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) 4
In such cases, the treatment approach can include established IC/BPS therapies as well as therapies more specific to CP/CPPS 4